Somatic mutations and the hierarchy of hematopoiesis

BioEssays

Volumn 32, Issue 11, 2010, Pages 1003-1008

  Traulsen, Arne ^a   Pacheco, Jorge M ^b,c   Luzzatto, Lucio ^d   Dingli, David ^e  

^a MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY   (Germany)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d ISTITUTO TOSCANO TUMORI   (Italy)

^e MAYO CLINIC   (United States)

Author keywords

Clonal evolution; Hematopoietic stem cells; Mutations; Progenitor cells; Stochastic dynamics

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2;

ARTICLE; CELL POPULATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; FLOW CYTOMETRY; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POPULATION; SOMATIC MUTATION; TARGET CELL;

ANIMALS; DISEASE; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMANS; JANUS KINASE 2; MUTATION; PHILADELPHIA CHROMOSOME;

EID: 77958188488     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201000025     Document Type: Article

References (54)

1. Kunkel TA, Bebenek K., 2000., DNA replication fidelity., Annu Rev Biochem, 69: 497-529.
2. Araten DJ, Golde DW, Zhang RH, et al., 2005., A quantitative measurement of the human somatic mutation rate., Cancer Res, 65: 8111-17.
3. Peruzzi B, Araten DJ, Notaro R, Luzzatto L., 2010., The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo, Mutat Res, 705: 3-10.
4. Cairns J., 1975., Mutation selection and the natural history of cancer., Nature, 255: 197-200.
5. Hanahan D, Weinberg RA., 2000., The hallmarks of cancer., Cell, 100: 57-70.
6. Vogelstein B, Kinzler KW., 2004., Cancer genes and the pathways they control., Nat Med, 10: 789-99.
7. Bodmer W, Bielas JH, Beckman RA., 2008., Genetic instability is not a requirement for tumor development., Cancer Res, 68: 3558-60 discussion 3560-3551.
8. Tomlinson I, Bodmer W., 1999., Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog., Nat Med, 5: 11-12.
9. Bose S, Deininger M, Gora-Tybor J, et al., 1998., The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease., Blood, 92: 3362-67.
10. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L., 1999., Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals., Proc Natl Acad Sci USA, 96: 5209-14.
11. Tefferi A, Gilliland G., 2006., Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system., Best Pract Res Clin Haematol, 19: 365-85.
12. Vainchenker W, Constantinescu SN., 2005. A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases. Hematology Am Soc Hematol Educ Program: 195-200.
13. Levine RL, Pardanani A, Tefferi A, Gilliland DG., 2007., Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders., Nat Rev Cancer, 7: 673-83.
14. Donohue DM, Reiff RH, Hanson ML, et al., 1958., Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood., J Clin Invest, 37: 1571-76.
15. Cronkite EP, Fliedner TM., 1964., Granulocytopoiesis., N Engl J Med, 270: 1347-52 CONTD.
16. Cronkite EP, Fliedner TM., 1964., Granulocytopoiesis., N Engl J Med, 270: 1403-08 CONCL.
17. McCulloch EA, Till JE., 1964., Proliferation of hemopoietic colony-forming cells transplanted into irradiated mice., Radiat Res, 22: 383-97.
18. Buescher ES, Alling DW, Gallin JI., 1985., Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool., J Clin Invest, 76: 1581-84.
19. Dingli D, Pacheco JM., 2006., Allometric scaling of the active hematopoietic stem cell pool across mammals., PLoS ONE, 1: e2.
20. Rufer N, Brummendorf TH, Kolvraa S, et al., 1999., Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood., J Exp Med, 190: 157-67.
21. Dingli D, Traulsen A, Pacheco JM., 2007., Compartmental architecture and dynamics of hematopoiesis., PLoS ONE, 2: e345.
22. Gordon MY, Blackett NM., 1994., Routes to repopulation-a unification of the stochastic model and separation of stem-cell subpopulations., Leukemia, 8: 1068-72 discussion 1072-63.
23. Abkowitz JL, Catlin SN, Guttorp P., 1996., Evidence that hematopoiesis may be a stochastic process in vivo, Nat Med, 2: 190-97.
24. Traulsen A, Pacheco JM, Dingli D., 2007., On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria., Stem Cells, 25: 3081-84.
25. Dingli D, Pacheco JM, Traulsen A., 2008., Multiple mutant clones in blood rarely coexist., Phys Rev E Stat Nonlin Soft Matter Phys, 77: 021915.
26. Dingli D, Luzzatto L, Pacheco JM., 2008., Neutral evolution in paroxysmal nocturnal hemoglobinuria., Proc Natl Acad Sci USA, 105: 18496-500.
27. Dingli D, Traulsen A, Pacheco JM., 2008., Chronic myeloid leukemia: origin, development, response to therapy, and relapse., Clin Leuk, 2: 133-39.
28. Lenaerts T, Pacheco JM, Traulsen A, Dingli D., 2009., Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells., Haematologica, 95: 900-7.
29. Dingli D, Traulsen A, Pacheco JM., 2007., Stochastic dynamics of hematopoietic tumor stem cells., Cell Cycle, 6: 461-66.
30. Shochat E, Stemmer SM, Segel L., 2002., Human haematopoiesis in steady state and following intense perturbations., Bull Math Biol, 64: 861-86.
31. Johnston MD, Edwards CM, Bodmer WF, et al., 2007., Examples of mathematical modeling: tales from the crypt., Cell Cycle, 6: 2106-12.
32. Johnston MD, Edwards CM, Bodmer WF, et al., 2007., Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer., Proc Natl Acad Sci USA, 104: 4008-13.
33. 137Cs gamma rays., Radiat Prot Dosimetry, 71: 279-82.
34. Aym S., 1976., Nonrandom distribution of chromosome breaks in cultured lymphocytes of normal subjects., Hum Genet, 32: 161-75.
35. Mattei MG., 1979., Distribution of spontaneous chromosome breaks in man., Cytogenet Cell Genet, 23: 95-102.
36. Rowley JD., 1973., Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining., Nature, 243: 290-93.
37. Jemal A, Siegel R, Ward E, et al., 2009., Cancer statistics, 2009., CA Cancer J Clin, 59: 225-49.
38. Pacheco JM, Traulsen A, Dingli D., 2009., The allometry of chronic myeloid leukemia., J Theor Biol, 259: 635-40.
39. Daley GQ, Van Etten RA, Baltimore D., 1990., Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome., Science, 247: 824-30.
40. Luzzatto L, Bessler M, Rotoli B., 1997., Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?, Cell, 88: 1-4.
41. Bessler M, Mason PJ, Hillmen P, Luzzatto L., 1994., Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria., Br J Haematol, 87: 863-66.
42. Araten DJ, Luzzatto L., 2006., The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH)., Blood, 108: 734-36.
43. Bessler M, Mason P, Hillmen P, Luzzatto L., 1994., Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria., Lancet, 343: 951-53.
44. Jamieson CH, Gotlib J, Durocher JA, et al., 2006., The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation., Proc Natl Acad Sci USA, 103: 6224-29.
45. Lacout C, Pisani DF, Tulliez M, et al., 2006., JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis., Blood, 108: 1652-60.
46. Rollison DE, Howlader N, Smith MT, et al., 2008., Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs., Blood, 112: 45-52.
47. Levine RL, Wadleigh M, Cools J, et al., 2005., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7: 387-97.
48. Nowak MA., 2006., Evolutionary dynamics., Cambridge: The Belknap Press of Harvard University Press.
49. Xu X, Zhang Q, Luo J, et al., 2007., JAK2(V617F): Prevalence in a large Chinese hospital population., Blood, 109: 339-42.
50. Tagariello G, Di Gaetano R, Sartori R, et al., 2009., The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels., Blood Transfus, 7: 111-16.
51. Huntly BJ, Shigematsu H, Deguchi K, et al., 2004., MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors., Cancer Cell, 6: 587-96.
52. Jamieson CH, Ailles LE, Dylla SJ, et al., 2004., Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML., N Engl J Med, 351: 657-67.
53. Krivtsov AV, Twomey D, Feng Z, et al., 2006., Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9., Nature, 442: 818-22.
54. Nowak MA, Michor F, Iwasa Y., 2003., The linear process of somatic evolution., Proc Natl Acad Sci USA, 100: 14966-69.